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Objective. To assess the safety and efficacy of a novel Wnt pathway modulator, lorecivivint (SM04690), for treating 
pain and inhibiting structural progression in moderately to severely symptomatic knee osteoarthritis (OA).
Methods. Subjects in this 52- week, phase IIa, multicenter, randomized, double- blind, placebo- controlled, dose- 
ranging trial received a single 2- ml intraarticular injection of lorecivivint (dose of 0.03 mg, 0.07 mg, or 0.23 mg) or 
placebo. Efficacy was assessed based on change from baseline on the Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC) score subscales for pain and function (scale 0–100 for each) and change from baseline 
in the radiographic medial joint space width (JSW). Baseline- adjusted analysis of covariance with multiple imputation 
was performed separately to evaluate efficacy. This proof- of- concept study evaluated the intent- to- treat population 
as well as a prespecified group of subjects with unilateral symptoms of knee OA (designated UNI) and an additional 
post hoc subgroup of subjects with unilateral symptoms but without widespread pain (designated UNI WP−).
Results. In this trial, 455 subjects were randomized to a treatment group. The primary end point, significant 
improvement in the WOMAC pain score compared with placebo at week 13, was not met by any lorecivivint dose 
group (mean ± SD change from baseline, −23.3 ± 2.2 in the 0.03 mg group, −23.5 ± 2.1 in the 0.07 mg group, −21.3 ± 
2.2 in the 0.23 mg group, and −22.1 ± 2.1 in the placebo group; each P > 0.05 versus placebo). All groups (including 
placebo) demonstrated clinically meaningful (≥20- point) improvements from baseline in the WOMAC pain score. 
The durability of response was evaluated through week 52. In the prespecified UNI group and post hoc UNI WP− 
group at week 52, treatment with 0.07 mg lorecivivint significantly improved the WOMAC pain score (between- group 
difference versus placebo, −8.73, 95% confidence interval [95% CI] −17.44, −0.03 [P = 0.049] and −11.21, 95% 
CI −20.99, −1.43 [P = 0.025], respectively) and WOMAC function score (between- group difference versus placebo, 
−10.26, 95% CI −19.82, −0.69 [P = 0.036] and −13.38, 95% CI −24.33, −2.43 [P = 0.017], respectively). Relative to 
baseline, the mean change in the medial JSW at week 52 was −0.04 mm in the 0.03 mg cohort, −0.09 mm in the 0.07 mg 
cohort, −0.16 mm in the 0.23 mg cohort, and −0.14 mm in the placebo cohort; no treatment group achieved a 
significant change in medial JSW compared with placebo at week 52. In both unilateral symptom subgroups, the 0.07 mg 
lorecivivint dose significantly increased medial JSW compared with placebo at week 52 (medial JSW 0.39 mm, 
95% CI 0.06, 0.72 in the UNI group [P = 0.021] and 0.42 mm, 95% CI 0.04, 0.80 in the UNI WP− group [P = 0.032]). 
Changes observed in the 0.03 mg and 0.23 mg dose groups were not significantly different from those in the placebo 
group for any of these measures. Lorecivivint appeared safe and well tolerated.
Conclusion. This phase IIa, proof- of- concept trial in patients with symptomatic knee OA did not meet its primary 
end point. Nevertheless, the study identified a target population in whom to evaluate the potential efficacy of 
lorecivivint for the treatment of knee OA.
ClinicalTrials.gov identifier: NCT02536833.
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INTRODUCTION
Knee osteoarthritis (OA) is a common, chronic disorder 
that is characterized by cartilage destruction, subchondral bone 
thickening, and osteophyte formation, leading to pain, functional 
limitation, and physical disability (1). The severity of knee OA is 
assessed by a combination of patient- reported outcome mea-
sures that include assessments of pain and function and objective 
structural measures such as radiologically assessed joint space 
narrowing (2). Pharmacologic interventions for knee OA man-
agement are symptom- alleviating treatments, including oral and 
topical nonsteroidal antiinflammatory drugs (NSAIDs), nonopioid 
analgesics, and intraarticular (IA) corticosteroid or hyaluronic acid 
injections (3,4). However, many of these treatments have limited 
short- term and long- term efficacy (4–7) and are associated with a 
high incidence of side effects. There remains a great unmet need 
for new treatments that provide symptom relief and even more of 
a need for disease- modifying OA drugs (DMOADs).
The Wnt pathway is integral for tissue homeostasis and 
regeneration (8,9) and is a key regulator of progenitor cell differ-
entiation in the knee joint (10). Cartilage homeostasis requires a 
balance of Wnt pathway activity. While necessary for chondrocyte 
differentiation and function (11), aberrant Wnt pathway activity in 
OA directs progenitor cell differentiation in the joint toward develop-
ment of osteoblasts instead of chondrocytes (12). Excessive acti-
vation of the Wnt pathway is known to increase OA susceptibility in 
animals and humans (13–16), whereas excessive inhibition of the 
Wnt pathway can cause cartilage and bone destruction (17–19). 
Therefore, a potential Wnt pathway–targeted DMOAD approach 
would need to maintain signaling within an optimal range.
Lorecivivint (SM04690) is a small- molecule Wnt pathway 
modulator currently in development as a potential DMOAD for the 
treatment of knee OA (20,21). Lorecivivint affects Wnt pathway 
activity via inhibition of 2 intranuclear targets, CDC- like kinase 2 
(CLK2) and dual- specificity tyrosine phosphorylation-regulated 
kinase 1A (DYRK1A), through which it acts both independent- 
ly and in combination to improve chondrocyte health and 
function while inhibiting inflammation (22). Preclinical studies, 
including repeat dosing in rats and dogs, have found the no- 
observed- adverse- effect level to be ~400 times the planned 
dose in humans (data on file). In vitro studies demonstrated 
that lorecivivint modulated Wnt signaling, reduced release 
of matrix- degrading enzymes from chondrocytes, demon-
strated anabolic activity in chondrocytes, and reduced STAT3 
signaling, NF- κB signaling, and inflammatory cytokine produc-
tion in synoviocytes (20). In a rat model of anterior cruciate 
ligament transection and partial medial meniscectomy-induced 
knee OA, a single IA injection of lorecivivint protected chondro-
cytes from catabolic breakdown (20).
In a previous phase I, randomized, placebo- controlled trial 
(n = 61), a single IA injection of lorecivivint at a dose of 0.03 mg, 
0.07 mg, or 0.23 mg administered into the target knee joint of sub-
jects with moderately to severely symptomatic knee OA appeared 
safe and well tolerated and showed no evidence of systemic 
exposure. While all lorecivivint and placebo groups demonstrated 
improvements from baseline in the Western Ontario and McMas-
ter Universities Osteoarthritis Index (WOMAC) pain and function 
subscale scores at week 24, the 0.07 mg lorecivivint treatment 
group demonstrated more favorable reductions in both WOMAC 
indices as compared with placebo. Treatment with 0.07 mg lore-
civivint also resulted in increased radiographic joint space width 
(JSW) beyond a minimum detectable difference of 0.13 mm (23), 
thus suggesting that lorecivivint may be a potential DMOAD for 
use in treating knee OA. Therefore, the objective of this phase IIa 
trial was to evaluate the safety and efficacy of lorecivivint among 
subjects with moderately to severely symptomatic knee OA.
SUBJECTS AND METHODS
Study design. This was a 52- week, phase IIa, multi-
center, randomized, double- blind, placebo- controlled, dose- 
ranging trial of 3 different dose concentrations of lorecivivint 
injected into the target (most painful) knee joint of subjects 
with moderately to severely symptomatic knee OA. This 
study was conducted at 36 clinical sites in the United States 
between September 2015 and April 2017. Subjects partici-
pated in a screening period of up to 21 days and were period-
ically observed during a 52- week follow- up period. Visits were 
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scheduled at screening, treatment visit day 1, and at follow- up 
weeks 4, 13, 26, 39, and 52.
On day 1, subjects were randomized to receive a single 
2- ml IA injection of lorecivivint at a dose of 0.03 mg, 0.07 mg, 
or 0.23 mg or phosphate buffered saline as placebo. These 
3 doses of lorecivivint corresponded to the lower, middle, 
and upper therapeutic ranges that were established previ-
ously in preclinical studies (data on file). Randomization was 
accomplished using Medidata Balance (Medidata Solutions, 
Inc.) such that eligible subjects were randomized at a ratio of 
1:1:1:1 using a permuted block design, with a block size of 
8 and stratification by site. An unblinded pharmacist at each 
site mixed the working dose from a common stock solution 
bottle, and an unblinded injector performed the injection. Ultra-
sound guidance and joint aspiration (up to 0.5 cc) were allowed 
if these were considered part of the site’s standard IA injec-
tion protocol for joint placement. All unblinded site personnel 
were instructed to minimize any contact with study subjects 
and were not allowed to perform any study assessments. All 
study investigators and subjects were blinded with regard to 
group assignment, and subject blinding was maintained by not 
allowing any subject to witness the injection.
This study was conducted in accordance with the ethics 
principles of the Declaration of Helsinki, the International Confer-
ence on Harmonisation Guidelines for Good Clinical Practice, and 
applicable regulations. The study protocol was approved by each 
clinic site’s independent ethics committee or institutional review 
board. All subjects provided written informed consent prior to par-
ticipating in any study- related procedures.
Subjects. Eligible subjects were ages 40–80 years with 
an established diagnosis of primary knee OA (established within 
≥6 months prior to study start) and fulfilled American College of 
Rheumatology clinical and radiographic classification criteria (24). 
Enrolled subjects were required to have Kellgren/Lawrence (K/L) 
radiographic disease stage 2 or stage 3 OA in their target knee 
(defined at screening as the knee with greater pain based on the 
subject’s evaluation and the investigator’s clinical judgment) (25). 
Subjects were required to have a pain visual analog scale (VAS) 
score of 30–80 mm (on 100- mm VAS) (26) and a WOMAC total 
score of 72–192 (of 240) (27) for the target knee at screening. 
There were no limitations on contralateral knee pain. Subjects 
were considered eligible if they were in good general health and 
ambulatory; assistive devices (e.g., canes) were allowed if needed 
<50% of the time, whereas any use of a walker was excluded.
Key exclusion criteria included male subjects with female 
partners of childbearing potential who refused to use an effec-
tive contraceptive method and women who were of childbear-
ing potential, pregnant, or lactating. Further exclusions included 
body mass index (BMI) >40 kg/m2, history of partial or complete 
joint replacement in the target knee, previous exposure to lore-
civivint, a major surgery (e.g., interventional arthroscopy) in the 
 target knee within 52 weeks prior to study medication injection, 
and any planned or elective surgery anywhere in the body dur-
ing the study period. Additional exclusion criteria included having 
comorbid conditions that could affect pain assessment of the tar-
get knee or a history of malignancy (except for in situ cancer or 
basal or squamous cell skin cancer) <5 years prior to injection. 
Subjects could not receive any IA injections of glucocorticoids, 
hyaluronic acid, or other therapeutic agents into either knee dur-
ing the study or within 2 months, 6 months, or 1 month prior to 
randomization, respectively. Electrotherapy or acupuncture for 
knee OA, chiropractic knee adjustments, or planned or elective 
surgery (e.g., arthroscopy) were also prohibited. Subjects could 
not take opioid analgesics or oral glucocorticoids during the study, 
although a stable background regimen of NSAIDs and acetami-
nophen was allowed provided that they were not taken within 24 
hours prior to study visits.
Data collection. Subject characteristics, medical his-
tory, weight, and height were collected at screening. Unilat-
eral or bilateral symptomatic knee OA status was designated 
by investigators at baseline based on the findings from history 
and physical examination. To assess comorbidity- related pain 
and symptoms, subjects completed the fibromyalgia diagnostic 
questionnaire, Widespread Pain Index (WPI) (total score range 
0–19), and Symptom Severity Scale (total score range 0–12) at 
screening (28).
Efficacy assessments. Efficacy assessments admin-
istered at all study visits included the WOMAC questionnaire 
(version NRS 3.1) to assess pain (subscale range 0–100 [no 
pain–extreme pain]) and function (subscale range 0–100 [no 
difficulty with daily activities–extreme difficulty]) and the patient 
global assessment of disease activity (PtGA) (VAS score range 
0–100 mm [“doing very well”–“doing very poorly”]). Fixed- flexion, 
posterior- anterior radiographs of the tibiofemoral compartments 
were obtained using a QuAP positioner at screening, week 26, 
and week 52. Quality control assessments of the radiographs 
were conducted at a central imaging laboratory (Medical Met-
rics Labs) in blinded manner (blinded with regard to treatment 
assignment), and medial JSW was measured using a landmark- 
based, fixed- location method.
The primary efficacy end point was the change from base-
line in WOMAC pain score in the target knee at week 13 in the 
0.07 mg lorecivivint group compared with the placebo group. 
Key secondary end points included 1) change from baseline in 
WOMAC pain score in the target knee at week 26, 2) change from 
baseline in WOMAC function score in the target knee at weeks 13 
and 26, 3) change from baseline in the PtGA score at weeks 13 
and 26, and 4) change from baseline in medial JSW in the target 
knee at week 26. Exploratory end points included 1) change from 
baseline in WOMAC pain and function scores in the target knee at 
weeks 4, 39, and 52, 2) change from baseline in the PtGA score at 
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weeks 4, 39, and 52, and 3) change from baseline in medial JSW 
in the target knee at week 52.
Safety. Safety was assessed by evaluating the incidence, 
severity, and seriousness of treatment- emergent adverse events 
(TEAEs) and clinically significant changes in clinical labora-
tory measures and vital signs; no formal statistical analyses were 
planned for safety outcomes. Safety measures were summarized 
for all treatment groups as treated, not as randomized.
Sample size. A sample size of ~445 subjects was planned 
for this trial based on standard statistical practice to establish an 
acceptable level of precision with respect to treatment effect esti-
mation (29); no formal calculation was used a priori to determine 
sample size. However, based on data from phase Ib trials and his-
torical data, a Monte Carlo simulation was conducted to estimate 
the possible power of using the WOMAC pain score (estimated 
power of 95.8%) and WOMAC function score (estimated power of 
78.5%) to estimate treatment effect given this sample size.
Statistical analysis. Statistical analyses were conducted 
using SAS version 9.4 (SAS Institute). Baseline characteris-
tics of the subjects in each treatment group are presented as 
the mean ± SD for continuous variables and as the frequency 
(proportion of patients) for categorical variables. Efficacy out-
come measures were evaluated using analysis of covari-
ance models adjusted for baseline values under the intent- to- treat 
(ITT) analysis set (i.e., comprising all subjects as randomized). 
Multiple imputation under the missing- at- random assumption was 
performed for efficacy outcomes with missing values. The least- 
squares estimate of the difference in change in the outcome from 
baseline at each time point between each lorecivivint dose group 
and placebo, adjusted for baseline value, is reported along with 
the 95% confidence intervals (95% CIs). The familywise error rate 
for the efficacy analyses was controlled in the strong sense (i.e., 
regardless of whether the global null hypothesis is true) using the 
closed, fixed- sequence testing method (30,31). Hypothesis tests 
were evaluated in a prespecified, sequential order that matched 
clinical inference from prior lorecivivint studies regarding the rel-
ative therapeutic benefit of each dose (the first hypothesis test 
evaluated the change in WOMAC pain score at week 13 between 
the 0.07 mg lorecivivint group and placebo group). If a hypothe-
sis test did not meet the critical significance level of α = 0.05, all 
subsequent tests were considered to be exploratory. The fixed 
sequence is detailed in the statistical analysis plan (see Sup-
plementary Table 1 [http://onlin elibr ary.wiley.com/doi/10.1002/
art.41315/ abstract]).
In support of the primary and secondary end points, interim 
analyses were conducted after all subjects completed the week 
26 visit and prior to completion of the trial at 52 weeks. An explor-
atory analysis was prespecified for a clinically relevant subject 
population with unilateral symptomatic knee OA (designated the 
UNI subgroup), defined on the basis of the history and physi-
cal examination identifying unilateral symptomatic knee OA. A 
second exploratory analysis was prespecified on the basis of 
the WPI score, but this analysis did not have sufficient data to 
pursue further. A post hoc exploratory analysis was subsequently 
completed based on subjects with unilateral symptomatic knee 
OA but without widespread pain (designated the UNI WP– 
subgroup), defined as having a WPI score of ≤4 and Symptom 
Severity Scale question 2 score of ≤2 (disregarding question 3).
A post hoc concordance analysis was conducted to esti-
mate the ability of one outcome to predict another outcome. It 
employed within- group logistic regression to estimate the likeli-
hood of baseline- adjusted changes in medial JSW being associ-
ated with positive clinical responses (i.e., achieving both WOMAC 
pain and WOMAC function score improvements of ≥50% [relative 
change] and ≥20 points [of 100]). The area under the curve (AUC) 
of receiver operator characteristic curves represented the con-
cordance between change in medial JSW and clinical response. 
Concordance was defined as “acceptable” when the AUC was 
>0.7 and “excellent” when the AUC was >0.8 (30); an AUC of 0.5 
represents concordance that is no better than statistical chance.
RESULTS
Subject disposition and baseline characteristics. 
Overall, 1,033 subjects were screened and 455 (44.0%) were 
randomized; 3 subjects were removed from the study prior to 
administration of a study drug injection (Figure 1). Cohorts of 112 
subjects, 117 subjects, 109 subjects, and 114 subjects were 
randomized to receive 0.03 mg lorecivivint, 0.07 mg lorecivivint, 
0.23 mg lorecivivint, or placebo, respectively. For subjects in the 
UNI group (n = 164), cohort sizes were 45 subjects, 35 subjects, 
45 subjects, and 39 subjects in the 0.03 mg lorecivivint, 0.07 mg 
lorecivivint, 0.23 mg lorecivivint, and placebo groups, respectively. 
For subjects in the UNI WP− group (n = 128), cohort sizes were 34 
subjects, 29 subjects, 33 subjects, and 32 subjects in the 0.03 mg 
lorecivivint, 0.07 mg lorecivivint, 0.23 mg lorecivivint, and placebo 
groups, respectively.
Among the subjects who completed the study, 103 (92%) 
were in the 0.03 mg cohort, 107 (91.5%) were in the 0.07 mg 
cohort, 95 (86.4%) were in the 0.23 mg cohort, and 97 (83.6%) 
were in the placebo cohort. At enrollment, the mean ± SD age 
of the subjects was 60.3 ± 8.7 years and the mean ± SD BMI 
was 29.9 ± 4.6 kg/m2. Overall, 268 (58.9%) of the enrolled sub-
jects were women, 392 (86.2%) were white, 292 (64.2%) had a 
K/L radiographic OA severity grade of 3 in the target knee, and 
164 (36.0%) were classified as having unilateral symptomatic dis-
ease (Table  1). Among the 424 subjects who were assigned a 
K/L radiographic severity grade for the nontarget knee, 386 (91%) 
had equal or worse radiographic disease in the nontarget knee. 
In general, the baseline characteristics of the subjects were bal-
anced between the treatment groups.
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Clinical outcomes. All subjects. The differences in 
change from baseline in WOMAC pain scores between the lore-
civivint dose groups and the placebo group were not statisti-
cally significant at week 13 (mean ± SD change from baseline, 
−23.3 ± 2.2 in the 0.03 mg group, −23.5 ± 2.1 in the 0.07 mg 
group, −21.3 ± 2.2 in the 0.23 mg group, and −22.1 ± 2.1 in 
the placebo group; each P > 0.05 versus placebo); thus, the 
primary end point was not met, and all analyses were  considered 
Figure 1. Disposition of the study subjects for the phase II, randomized trial of lorecivivint (SM04690) versus placebo and primary reasons 
for discontinuation. AE = adverse event.










Age, mean ± SD years 59.0 ± 9.0 60.0 ± 8.2 61.3 ± 8.7 60.7 ± 8.9
Body mass index, mean ± SD kg/m2 29.77 ± 4.81 30.81 ± 4.74 29.64 ± 4.45 29.17 ± 4.40
Female, no. (%) 68 (60.7) 60 (51.3) 68 (61.8) 72 (62.1)
Race/ethnicity, no. (%)
White 92 (82.1) 102 (87.2) 96 (87.3) 102 (87.9)
African American 18 (16.1) 14 (12.0) 12 (10.9) 10 (8.6)
Hispanic or Latino 20 (17.9) 23 (19.7) 17 (15.5) 21 (18.1)
Other 2 (1.8) 1 (0.9) 2 (1.8) 4 (3.4)
K/L grade 3 radiographic OA, no. (%) 74 (66.1) 74 (63.2) 70 (63.6) 74 (63.8)
Unilateral symptomatic knee OA, no. (%) 45 (40.2) 35 (29.9) 45 (40.9) 39 (33.6)
WPI ≤4 and SS Scale score ≤2, no. (%) 73 (65.2) 79 (67.5) 76 (69.1) 75 (64.7)
* K/L = Kellgren/Lawrence; OA = osteoarthritis; WPI = Widespread Pain Index; SS = Symptom Severity (question 2). 
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 exploratory. However, subjects in all of the lorecivivint dose 
groups and the placebo group achieved at least a 20- point mean 
improvement from baseline in the WOMAC pain and function 
subscale scores at week 13 through week 52 and in the PtGA 
score at all time points postinjection (Figures 2A and 3A, and 
Supplementary Figure 1A, available on the Arthritis & Rheuma-
tology website at http://onlin elibr ary.wiley.com/doi/10.1002/
art.41315/ abstract). Treatment with 0.07 mg lorecivivint led to 
numerically larger improvements from baseline in the pain and 
function scores as compared with treatment with either the 
0.03 mg or 0.23 mg dose of lorecivivint. This was apparent start-
ing at 13 weeks postinjection and continued through 52 weeks.
UNI group. Among the subjects in the UNI subgroup, 
those receiving the 0.07 mg dose of lorecivivint demonstrat-
ed improvements in baseline- adjusted change in WOMAC 
pain and function scores compared with placebo at week 
13, which continued through week 52 (Figures  2B and 3B). 
At week 52, the 0.07 mg lorecivivint group had significantly 
lower scores on the WOMAC pain subscale compared with 
the placebo group (between- group difference, −8.73, 95% 
Figure 2. Mean scores on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale over time (left) and 
ladder plots (mean and 95% confidence intervals) of baseline- adjusted change from baseline in the WOMAC pain scores (right), comparing the 
lorecivivint (LOR) dose groups and the placebo group over time in the intent- to- treat (ITT) analysis set (A), subjects with unilateral symptomatic 
knee osteoarthritis (OA) (B), and subjects with unilateral symptomatic knee OA but without widespread pain (WP–) (C).
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CI  −17.44, −0.03; P = 0.049) and significantly lower scores 
on the WOMAC function subscale compared with the place-
bo group (between- group difference, −10.26, 95% CI −19.82, 
−0.69; P = 0.036). In this subgroup of patients with unilateral 
symptomatic knee OA, there were no significant differences 
in either the WOMAC pain score or WOMAC function score 
between the 0.03 mg or 0.23 mg lorecivivint dose groups 
compared with the placebo group (Figures 2B and 3B). The 
0.03 mg treatment group showed significant improvement in 
the PtGA score compared with the placebo group at weeks 
13 and 26 (see Supplementary Figure 1B [http://onlin elibr ary.
wiley.com/doi/10.1002/art.41315/ abstract]).
UNI WP− group. Among the subjects in the UNI WP− sub-
group, those receiving 0.07 mg lorecivivint demonstrated sig-
nificant improvements in the WOMAC pain and function scores 
compared with the placebo group. The between- group differ-
ence in the WOMAC pain score was −9.11 (95% CI −17.75, 
−0.47) (P = 0.039) at week 26, −11.83 (95% CI −23.23, −0.42) 
(P = 0.042) at week 39, and −11.21 (95% CI −20.99, −1.43) 
(P = 0.025) at week 52. The between- group difference in the 
Figure 3. Mean scores on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function subscale over time (left) 
and ladder plots (mean and 95% confidence intervals) of baseline- adjusted change from baseline in the WOMAC function scores (right), 
comparing the lorecivivint (LOR) dose groups and the placebo group over time in the intent- to- treat (ITT) analysis set (A), subjects with unilateral 
symptomatic knee osteoarthritis (OA) (B), and subjects with unilateral symptomatic knee OA but without widespread pain (WP–) (C).
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WOMAC function score was −9.62 (95% CI −18.14, −1.10) (P = 
0.027) at week 26, −11.57 (95% CI −22.31, −0.82) (P = 0.035) 
at week 39, and −13.38 (95% CI −24.33, −2.43) (P = 0.017) at 
week 52 (Figures 2C and 3C). In this subgroup of patients with 
unilateral symptomatic knee OA but without widespread pain, 
there were no significant differences in change in pain or func-
tion scores between the 0.03 mg or 0.23 mg lorecivivint dose 
groups and the placebo group (Figures 2C and 3C). However, 
the 0.03 mg treatment group showed a significant improvement 
in the PtGA score compared with the placebo group at week 13, 
and both the 0.03 mg and 0.07 mg treatment groups showed 
significant improvements in the PtGA score compared with the 
placebo group at week 26 in this post hoc analysis (see Supple-
mentary Figure 1C [http://onlin elibr ary.wiley.com/doi/10.1002/
art.41315/ abstract]).
Radiographic outcomes. All subjects. Compared 
with the values at baseline, the mean change in medial JSW 
was −0.07 mm at week 26 and −0.04 mm at week 52 in the 
0.03 mg cohort, −0.11 mm at week 26 and −0.09 mm at 
week 52 in the 0.07 mg cohort, −0.02 mm at week 26 and 
−0.16 mm at week 52 in the 0.23 mg cohort, and −0.20 mm 
Figure 4. Mean medial joint space width (JSW) measurements over time (left) and ladder plots (mean and 95% confidence intervals) of 
baseline- adjusted change from baseline in the medial JSW (right), comparing the lorecivivint (LOR) dose groups and the placebo group over 
time in the intent- to- treat (ITT) analysis set (A), subjects with unilateral symptomatic knee osteoarthritis (OA) (B), and subjects with unilateral 
symptomatic knee OA but without widespread pain (WP–) (C).
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at week 26 and −0.14 mm at week 52 in the placebo cohort 
 (Figure 4A). At week 26, the mean change in medial JSW in 
those receiving the 0.23 mg dose of lorecivivint was signifi-
cantly different from that in the placebo group (between- group 
difference, 0.19 mm, 95% CI 0.02, 0.36; P = 0.032). At week 
52, the mean change in medial JSW in the 0.03 mg and 
0.07 mg lorecivivint dose groups was similar to that seen 
at week 26, whereas the mean change in the 0.23 mg lore-
civivint dose group and placebo group had declined (Fig-
ure  4A). Among all subjects, both treatment with 0.03 mg 
lorecivivint (at week 52, change from baseline −0.04 mm) 
and treatment with 0.07 mg lorecivivint (at week 52, change 
from baseline −0.09 mm), but not treatment with 0.23 mg 
lorecivivint, maintained the medial JSW when compared with 
that in the placebo group (at week 52, change from baseline 
−0.14 mm); however, the differences were not statistically 
significant.
UNI group. Subjects in the UNI subgroup treated with 
0.07 mg lorecivivint showed improvements in the medial JSW 
at weeks 26 and 52 (mean change from baseline 0.26 mm and 
0.19 mm, respectively), whereas subjects in the UNI subgroup 
treated with placebo showed worsening of medial JSW (mean 
change from baseline −0.26 mm and −0.21 mm, respective-
ly) (Figure 4B). The differences between the 0.07 mg loreciviv-
int group and the placebo group were significant at both time 
points; the mean change in medial JSW was 0.52 mm (95% CI 
0.15, 0.89) at week 26 (P = 0.006) and 0.39 mm (95% CI 0.06, 
0.72) at week 52 (P = 0.021). Among these subjects with unilat-
eral symptomatic knee OA, there were no significant differences 
in the change in medial JSW when comparing the 0.03 mg or 
0.23 mg lorecivivint group with the placebo group (Figure 4B).
UNI WP− group. In the UNI WP− subgroup, the 0.07 mg 
lorecivivint treatment group demonstrated improved medial 
JSW at week 26 (mean change from baseline 0.28 mm) and 
week 52 (mean change from baseline 0.17 mm), whereas the 
placebo treatment group had worsening of medial JSW at 
both time points (mean change from baseline −0.26 mm and 
−0.26 mm, respectively) (Figure 4C). The differences between 
the 0.07 mg lorecivivint group and the placebo group were sig-
nificant at both time points (between- group difference, 0.53 mm, 
95% CI 0.10, 0.97 at week 26 [P = 0.016] and 0.42 mm, 95% 
CI 0.04, 0.80 at week 52 [P = 0.032]). Subjects with unilateral 
symptomatic OA but without widespread pain in the 0.03 mg 
or 0.23 lorecivivint treatment groups showed no significant dif-
ferences in change in medial JSW compared with the placebo 
group (Figure 4C).













Total TEAEs 142/61 (55.0) 147/65 (57.0) 107/47 (45.2) 117/53 (49.1) 547/237 (52.4)
Arthralgia 16/13 (11.7) 14/13 (11.4) 13/9 (8.7) 12/10 (9.3) 61/49 (10.8)
Back pain 0/0 (0.0) 2/2 (1.8) 1/1 (1.0) 2/2 (1.9) 5/5 (1.1)
Bronchitis 2/2 (1.8) 3/3 (2.6) 3/2 (1.9) 1/1 (0.9) 9/8 (1.8)
Bursitis 2/2 (1.8) 3/2 (1.8) 2/2 (1.9) 0/0 (0.0) 7/6 (1.3)
Contusion 1/1 (0.9) 2/2 (1.8) 3/3 (2.9) 2/2 (1.9) 8/8 (1.8)
Cystitis 0/0 (0.0) 3/3 (2.6) 2/1 (1.0) 1/1 (0.9) 6/5 (1.1)
Fall 2/2 (1.8) 2/2 (1.8) 0/0 (0.0) 1/1 (0.9) 5/5 (1.1)
Gastroenteritis 3/3 (2.7) 0/0 (0.0) 1/1 (1.0) 1/1 (0.9) 5/5 (1.1)
Headache 0/0 (0.0) 6/3 (2.6) 2/2 (1.9) 4/4 (3.7) 13/10 (2.2)
Hypertension 0/0 (0.0) 4/4 (3.5) 4/4 (3.8) 3/3 (2.8) 11/11 (2.4)
Increased AST level 2/2 (1.8) 1/1 (0.9) 0/0 (0.0) 2/2 (1.9) 5/5 (1.1)
Influenza 4/4 (3.6) 0/0 (0.0) 2/2 (1.9) 0/0 (0.0) 6/6 (1.3)
Joint effusion 5/4 (3.6) 2/2 (1.8) 1/1 (1.0) 2/2 (1.9) 10/9 (2.0)
Joint injury 2/2 (1.8) 0/0 (0.0) 1/1 (1.0) 1/1 (0.9) 6/6 (1.3)
Joint swelling 5/3 (2.7) 4/4 (3.5) 2/2 (1.9) 6/5 (4.6) 17/14 (3.1)
Meniscus injury 2/2 (1.8) 2/2 (1.8) 0/0 (0.0) 0/0 (0.0) 5/5 (1.1)
Nasopharyngitis 4/4 (3.6) 3/3 (2.6) 3/3 (2.9) 0/0 (0.0) 11/11 (2.4)
Nausea 2/2 (1.8) 1/1 (0.9) 2/2 (1.9) 1/1 (0.9) 6/6 (1.3)
Noncardiac chest pain 1/1 (0.9) 2/2 (1.8) 1/1 (1.0) 1/1 (0.9) 6/6 (1.3)
Osteoarthritis 4/3 (2.7) 2/2 (1.8) 3/3 (2.9) 5/3 (2.8) 14/11 (2.4)
Sinusitis 1/1 (0.9) 2/2 (1.8) 1/1 (1.0) 5/5 (4.6) 9/9 (2.0)
Tendinitis 3/3 (2.7) 1/1 (0.9) 1/1 (1.0) 1/1 (0.9) 6/6 (1.3)
Upper respiratory tract infection 5/5 (4.5) 2/2 (1.8) 1/1 (1.0) 3/3 (2.8) 12/12 (2.7)
Urinary tract infection 2/2 (1.8) 2/2 (1.8) 3/2 (1.9) 3/3 (2.8) 10/9 (2.0)
* Values are the number of reported treatment- emergent adverse events (TEAEs)/number of unique subjects reporting the 
event (% of treatment group). AST = aspartate aminotransferase. 
† The group of all subjects includes those who received a dose of lorecivivint or placebo that was not specified per protocol 
(n = 15). 
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Concordance between change in medial JSW and clini-
cal response. In the all- subjects analysis, no treatment group 
achieved an AUC of >0.7 (a measure of concordance between 
change in medial JSW and clinical response) (see Supplementary 
Figure 2A, available on the Arthritis & Rheumatology website at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41315/ abstract). 
Among subjects receiving the 0.07 mg dose of lorecivivint, con-
cordance was “acceptable” (AUC 0.783) in the UNI subgroup and 
“excellent” (AUC 0.825) in the UNI WP− subgroup (Supplemen-
tary Figures 2B and C [http://onlin elibr ary.wiley.com/doi/10.1002/
art.41315/ abstract]). No other doses in either subgroup achieved 
an AUC >0.7.
Safety. No clinically significant safety concerns with respect 
to vital signs, clinical laboratory results, or AEs were observed; 
rates were comparable between the lorecivivint and placebo 
groups. No deaths were reported during the study. Fifteen sub-
jects incorrectly received a study injection that diverged from 
that prescribed by the protocol; these subjects are described as 
“Other” in the safety analysis.
In total, 547 TEAEs were reported by 237 subjects (52.4% 
of 452 subjects), of which 40 AEs in 32 subjects (7.1%) were 
deemed related to the study drug by the investigator (Table 2). 
Among the treatment groups, 142 TEAEs were reported by 61 
subjects in the 0.03 mg cohort (55.0% of 111 treated subjects), 
147 TEAEs by 65 subjects in the 0.07 mg cohort (57.0% of 114 
treated subjects), 107 TEAEs by 47 subjects in the 0.23 mg 
cohort (45.2% of 104 treated subjects), 117 TEAEs by 53 sub-
jects in the placebo cohort (49.1% of 108 treated subjects), and 
34 TEAEs by 11 subjects who were classified in the “Other” dose 
group (73.3% of 15 subjects). Arthralgia, defined for this study as 
an exacerbation (increase in frequency, severity, or specificity) of 
an existing condition, was the most common AE reported across 
all study cohorts with 61 AEs reported by 49 subjects (10.8% of 
452 treated subjects); 38 AEs in 36 subjects (8.0% of the 452 
treated subjects) were reported to occur in the target knee. There 
were 10 AEs in 10 subjects that occurred in the nontarget knee 
and 12 AEs in 11 subjects that were reported to occur in other 
(non- knee) joints (7 hips, 4 elbows, and 1 wrist).
Twenty- nine serious adverse events (SAEs) were reported 
by 17 subjects (3.8% of 452 subjects), and all were deemed 
unrelated to the study drug by the investigator. Seven SAEs 
were reported by 5 subjects in the 0.03 mg cohort (4.5% of 
111 treated subjects), 12 SAEs by 4 subjects in the 0.07 mg 
cohort (3.5% of 114 treated subjects), 5 SAEs by 4 subjects 
in the 0.23 mg cohort (3.8% of 104 treated subjects), 3 SAEs 
by 3 subjects in the placebo cohort (2.8% of 108 treated 
subjects), and 2 SAEs by 1 subject who received an uni-
dentified dose (6.7% of 15 subjects in the “Other” group). 
Within the 0.07 mg cohort, 6 cardiovascular SAEs were 
reported by 1 subject. The other 6 SAEs that occurred in the 
0.07 mg cohort were distributed among the other 3 subjects 
within this cohort. The most common SAEs included infec-
tions and cardiac disorders (see Supplementary Table 2 [http://
onlinelibrary.wiley.com/doi/10.1002/art.41315/abstract]).
DISCUSSION
In this phase IIa, 52- week, randomized, placebo- controlled, 
proof- of- concept clinical trial among subjects with moderately to 
severely symptomatic knee OA, there was no statistically signifi-
cant difference in improvement in WOMAC pain scores between 
treatment groups at week 13. However, IA injection of lorecivivint 
generally appeared safe and well tolerated. There were no mean-
ingful differences in the incidence of AEs between the lorecivivint 
dose groups and the placebo group. Moreover, no SAEs were 
deemed related to the study treatment by the investigators.
Though the primary end point of this study was not met, 
additional preplanned and post hoc analyses of these data sug-
gest that IA injection of lorecivivint could have potential efficacy in 
the treatment of knee OA. Even though there were no statistically 
significant differences (including improvement in WOMAC pain 
scores, the primary end point) between the placebo and any of 
the lorecivivint dose groups in the all- subjects analysis, if a min-
imal clinically important difference threshold of a 10% (10- point) 
change in score (32) were to be applied, both lorecivivint and pla-
cebo would be found to produce clinically meaningful improve-
ments from baseline in the WOMAC pain and function subscales.
Analysis of the prespecified UNI subgroup showed greater 
improvements in WOMAC pain scores, WOMAC function scores, 
and medial JSW for the 0.07 mg cohort compared with the pla-
cebo cohort. These differences appeared to be further enhanced 
in the post hoc analysis of subjects in the UNI WP− subgroup 
receiving 0.07 mg lorecivivint. Pain reporting by subjects with 
bilateral symptomatic knee OA is known to be complicated, not 
only because of the presence of contralateral knee pain, but also 
because other joints may be affected by OA (33,34), nociceptive 
biomechanical factors may be involved, and other centralized pain 
conditions (e.g., fibromyalgia) may be present (35). Therefore, the 
improvements compared with placebo observed in both the UNI 
and the UNI WP− subgroups versus the all- subjects group after 
an IA injection of lorecivivint into the target knee may be attribut-
able to a predominance of subjects with unilateral OA symptoms 
being able to discriminate their target knee pain from other pain 
sources. These results inform the design of future lorecivivint trials 
by identifying a target population in whom potential symptomatic 
efficacy could be more clearly delineated.
In addition to symptom improvements, inhibition of struc-
tural progression is a key goal of disease modification in OA 
(36); in fact, the slowing of joint space narrowing has been rec-
ommended as an appropriate structural end point for DMOAD 
trials (36). In the all- subjects analysis, both 0.03 mg lorecivivint (at 
week 52, change from baseline in medial JSW −0.04 mm) and 
0.07 mg lorecivivint (at week 52, change from baseline in medial 
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JSW −0.09 mm) maintained, at least numerically, the medial JSW 
at week 52, but neither dose achieved a significant difference 
when compared with placebo (at week 52, change from base-
line in medial JSW −0.14 mm). Subjects with unilateral symptom-
atic OA (i.e., both the UNI and the UNI WP− subgroups) treated 
with 0.07 mg lorecivivint showed mean medial JSW increases 
beyond a 0.13- mm minimum detectable difference (23), whereas 
subjects who received placebo showed decreases (narrowing) 
in mean medial JSW from baseline. Joint space narrowing has also 
been correlated with clinical outcomes, including an increased risk 
of total knee replacement in those with joint space narrowing of 
>0.5 mm over 2 years (an outcome indicative of treatment failure) 
(36,37). Knee OA is associated with typical joint space narrowing 
of 0.1–0.3 mm per year (38,39); although such changes require 
precise and reproducible measurement methods, such as the 
positioned, fixed- flexion radiography technique employed herein, 
the accuracy of the knee radiographic measurement of medial 
JSW can range from 0.04 mm to 0.5 mm (23,40–42). The rel-
ative improvement in medial JSW in the unilateral symptomatic 
subject subgroups may also be related to a more favorable local 
biomechanical environment in individuals with unilateral knee pain 
(43,44).
A post hoc analysis of both the UNI and the UNI WP− sub-
groups demonstrated that the radiographic findings (medial 
JSW) and clinical findings (WOMAC pain and function scores) in 
the 0.07 mg dose group were concordant (i.e., the change in the 
former is associated with change in the latter). This suggested 
a connection between improvement in structural measures and 
improvement in clinical responses. The 2018 draft guidance 
from the US Food and Drug Administration on OA structural end 
points suggests that additional data are needed to support the 
relationship between structural measurements and clinical out-
comes; this analysis sought to contribute to this growing evi-
dence base.
This phase IIa study has several limitations, including no for-
mal, preplanned sample size or power calculation and consider-
able placebo responses for patient- reported outcomes, similar 
to those demonstrated in other OA trials (5,45). Although trials 
investigating IA therapies for knee OA commonly use saline as a 
placebo comparator arm, evidence suggests that IA saline might 
actually be therapeutic (46). Therefore, further studies of loreciviv-
int in larger clinical trials with refined inclusion criteria (e.g., focus-
ing on subjects with unilateral symptomatic OA, as lorecivivint 
is administered into the single most painful knee) are needed to 
disentangle the active treatment effects from the placebo effects. 
Although radiographic medial JSW represents an objective mea-
sure for assessing structural progression, the evidence support-
ing the usefulness of this measurement is not definitive and other 
imaging modalities, such as magnetic resonance imaging, may 
also be considered. Larger and longer studies are needed to 
determine the best methods for assessing the disease- modifying 
abilities of drugs in knee DMOAD trials.
Finally, the primary statistical analysis Type 1 error control 
strategy was not achieved, leading to all statistical results being 
considered exploratory. Since the (prespecified) UNI and (post 
hoc) UNI WP− groups were small with respect to the number of 
subjects, the results of these exploratory analyses in both groups 
are considered to be hypothesis generating, and thus require val-
idation in a prospective trial.
In summary, although the primary end point in all subjects 
was not met, treatment of subjects with moderately to severely 
symptomatic knee OA in the UNI and UNI WP− subgroups with an 
IA injection of 0.07 mg lorecivivint resulted in numerical improve-
ments in pain, function, and medial JSW compared with placebo. 
Furthermore, treatment with 0.07 mg of lorecivivint demonstrated 
the greatest improvements in WOMAC pain and function scores 
and the highest concordance between symptom relief and struc-
tural changes. This study identified a target group of subjects with 
unilateral symptomatic knee OA and a potentially optimal dose 
of lorecivivint (0.07 mg). The clinical and radiographic outcomes 
warrant additional studies of the potential of lorecivivint for both 
analgesia and disease- modifying activity in knee OA.
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Clinical Images: Cholesterol and monosodium urate monohydrate crystals in synovial fluid from a patient with gout
The patient, a 66- year- old man, presented with a 1- week history of left elbow pain and swelling. He denied experiencing any prior trauma 
or fever. He had a history of diabetes mellitus, hypertension, hyperlipidemia, and chronic kidney disease. Five years earlier, he had devel-
oped podagra and was diagnosed as having gout, which was treated with indomethacin. He did not take any urate- lowering medication. 
At current presentation, he reported experiencing multiple episodes of gout per year, mostly affecting the feet. Physical examination of the 
left elbow revealed swelling, tenderness, warmth, erythema, and decreased range of motion. Examination of synovial fluid by polarized 
light microscopy revealed cholesterol crystals and monosodium urate monohydrate (MSU) crystals. In A and B, cholesterol appears as 
plate- like structures with notched corners and MSU appears as needle- shaped crystals with negative birefringence (appearing yellow or 
blue when viewed with a first- order red plate compensator parallel or perpendicular to the axis, respectively; arrows depict the axis of the 
compensator) (original magnification × 200 in A; × 400 in B). Gram stain and bacterial cultures were negative. Symptoms resolved after a 
5- day course of oral glucocorticoid treatment; after which urate- lowering therapy was started. Cholesterol crystals are occasionally seen in 
chronically inflamed joints in rheumatoid arthritis (1,2) and bursa effusions (2), and there have been rare reports of their presence in chronic 
tophaceous gout (3). They are extracellular and can be present in association with Maltese cross–shaped fat droplets. Cholesterol crystals 
typically appear as large, flat, rectangular plates and have notched corners with varying birefringence. These features enable differentiation 
from MSU crystals, which are needle- shaped and strongly negatively birefringent.
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